June 9, 2025 02:27 PM EDT

FDA adds biomarker limits to stomach, esophageal cancer labels for Merck's Keytruda and BMS' Opdivo

Zachary Brennan

Senior Editor

The FDA late last month sent letters to Merck and Bristol Myers Squibb telling them that their blockbuster cancer drugs Keytruda and Opdivo should be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA adds biomarker limits to stomach, esophageal cancer labels for Merck's Keytruda and BMS' Opdivo

Zachary Brennan

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: HHS chief Kennedy removes all ACIP members, dismantling vaccine board

Biotech slump forces Resilience to wind down six manufacturing sites, using bankruptcy move

Updated: Merck wins FDA approval for RSV antibody drug, making a hot market more competitive

Merck says its oral PCSK9 inhibitor ‘significantly’ cut cholesterol in two Phase 3 trials

In a break from other biotechs, Twist Bioscience throws support behind tariffs on synthetic DNA

McKesson leads the charge in revolutionizing precision oncology in community practices

FDA adds bio­mark­er lim­its to stom­ach, esophageal can­cer la­bels for Mer­ck­'s Keytru­da and BM­S' Op­di­vo

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA adds biomarker limits to stomach, esophageal cancer labels for Merck's Keytruda and BMS' Opdivo